Stereotaxis, Inc. (STXS)
| Market Cap | 133.64M |
| Revenue (ttm) | 33.44M |
| Net Income (ttm) | -14.61M |
| Shares Out | 74.66M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 585,370 |
| Open | 1.81 |
| Previous Close | 1.75 |
| Day's Range | 1.78 - 1.83 |
| 52-Week Range | 1.72 - 10.30 |
| Beta | 1.73 |
| Analysts | Buy |
| Price Target | 10.46 (+484.4%) |
| Earnings Date | May 10, 2022 |
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to ma...
Financial Performance
In 2021, Stereotaxis's revenue was $35.02 million, an increase of 31.51% compared to the previous year's $26.63 million. Losses were -$10.72 million, 61.2% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for STXS stock is "Buy." The 12-month stock price forecast is 10.46, which is an increase of 484.36% from the latest price.
News
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0% and 0.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Stereotaxis Reports 2022 First Quarter Financial Results
ST. LOUIS, May 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results ...
Heart Centre Rigshospitalet Copenhagen Celebrates 5,000 Robotic Cardiac Ablation Procedures
Denmark's only robotic cardiac electrophysiology team is recognized for leading the world in treating the most heart rhythm patients using Stereotaxis' advanced robotic technology Denmark's only robotic...
National Institute of Cardiology Becomes First Hospital in Poland to Establish Advanced Robotic Program to Treat Hear...
Stereotaxis robotic technology now in use in 25 countries Stereotaxis robotic technology now in use in 25 countries
Stereotaxis Announces Grand Opening of New Global Headquarters in St. Louis
Company joins Downtown North Urban Insight District in unique mixed-use space to accomodate growing surgical robotics business Company joins Downtown North Urban Insight District in unique mixed-use spa...
Stereotaxis Inc. (STXS) Reports Q4 Loss, Tops Revenue Estimates
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -25% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Stereotaxis Reports 2021 Full Year Financial Results
ST. LOUIS, March 03, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial result...
Stereotaxis to Present at Upcoming Investor Conferences
ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fisch...
Stereotaxis to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022
ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will rel...
Fuwai Central China Cardiovascular Hospital Becomes First to Offer Advanced Robotic Treatment for Heart Rhythm Disord...
ST. LOUIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Fuwai Central China C...
HonorHealth Scottsdale Shea Medical Center Builds Advanced Robotic Program to Treat Heart Rhythm Disorders
ST. LOUIS, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that HonorHealth has estab...
Stereotaxis Robotic Technology Reduces Incidence of Silent Cerebral Embolism During Atrial Fibrillation Ablation in N...
ST. LOUIS, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in Fr...
Stereotaxis to Host Inaugural Innovation Day – Pioneering Endovascular Robotics
ST. LOUIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it will host an ...
BJC HealthCare Becomes First Health Care System in Midwest to Adopt Latest Robotic Technology for Arrhythmia Treatment
ST. LOUIS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces today that BJC HealthCare h...
Stereotaxis Reports 2021 Third Quarter Financial Results
ST. LOUIS, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for...
Stereotaxis Technology, Clinical Value and Innovations to be Highlighted at Society for Cardiac Robotic Navigation Me...
ST. LOUIS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announces it will attend the F...
Earnings Preview: Stereotaxis Inc. (STXS) Q3 Earnings Expected to Decline
Stereotaxis Inc. (STXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stereotaxis to Report Third Quarter 2021 Financial Results on November 11, 2021
ST. LOUIS, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release...
First Patients Treated in Southern Europe with Stereotaxis Genesis Robotic Technology
ST. LOUIS, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced installation of its ...
Stereotaxis and MicroPort EP Collaborate to Advance Innovation and Adoption of Robotic Electrophysiology in China
ST. LOUIS and SHANGHAI, China, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai Microport EP Medtech Co., Ltd. (“MicroPort EP”) today announced a broad collaboration to advance te...
Stereotaxis Inc. (STXS) Reports Q2 Loss, Tops Revenue Estimates
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 33.33% and 10.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Stereotaxis Reports 2021 Second Quarter Financial Results
ST. LOUIS, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for...
Stereotaxis Inc. (STXS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Stereotaxis Inc. (STXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stereotaxis Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.
ST. LOUIS, July 26, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of M...
Here's Why "Trend" Investors Would Love Betting on Stereotaxis Inc. (STXS)
If you are looking for stocks that are well positioned to maintain their recent uptrend, Stereotaxis Inc. (STXS) could be a great choice. It is one of the several stocks that passed through our "Recent ...